AstraZeneca, Valeant Pharmaceuticals deal

The companies terminated the European portion of a deal granting Valeant rights to develop and commercialize brodalumab ( KHK4827) outside of Japan and other Asian territories. Under the termination, Valeant will receive an undisclosed upfront payment and is eligible for sales milestones and AstraZeneca will receive a reduced pre-launch milestone payment from Valeant. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151, Tokyo, Japan) has rights in Japan and other Asian territories under a deal with Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.). Amgen withdrew from a collaboration with AZ to co-develop the human IgG2 mAb against IL-17 receptor (IL17R; IL17RA), citing safety concerns. ...